Form 4 for LAB STANDARD BIOTOOLS INC.
Accepted 2025-02-24 00:00:00 ET · period of report 2025-02-20 · accession 0000950170-25-025806 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-02-24 | 2025-02-20 | LAB | Egholm Michael | Pres, CEO, Dir | F - Tax | $1.39 | -31.0K | 1.45M | -2% | -$43.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-20 | F | D | 31,031 | $1.39 | 1,447,673 | D | — | — | (F1) The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units granted to the reporting person on May 20, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 21, 2024. (F2) Includes 5,000 shares of common stock acquired by the reporting person on May 31, 2024 under the Issuer's Employee Stock Purchase Plan. |